Feature | November 15, 2006| Ryan Hiett

Heart Central

When a “top 5” hospital and leading heart-assist

The AB5000 Circulatory Support Device from Abiomed Inc.

The AB5000 Circulatory Support Device from Abiomed Inc.

The AB5000 Circulatory Support Device from Abiomed Inc.

If its cancer care, emergency medicine, pediatric and maternal-fetal medicine specialties keep Robert Wood Johnson University Hospital (RWJUH) in New Brunswick at the forefront of nationally recognized hospitals, its heart center is what keeps it pumping.
The Heart Center of New Jersey, a 225-bed hospital-within-a-hospital, has excelled in providing primary angioplasty to heart attack patients, according to the U.S. Department of Health and Human Services’ Hospital Compare Web site, and was ranked in the state’s top five hospitals for heart attack care by the New Jersey Department of Health and Senior Services.
The center includes one of the busiest cardiac cath labs in the region. The Dr. Norman Reitman Cardiac Catheterization Laboratories is made up of seven labs, including two for cardiac electrophysiology. The suite handles more than 12,000 procedures each year.
In addition to diagnostic cath and coronary interventional procedures, cardiologists there are also performing peripheral vascular interventions in the labs.
The center houses RWJUH's Advanced Heart Failure and Transplant Cardiology Program, which offers heart treatments that include specialized medical, device and surgical therapy. The program offers care for patients with end-stage heart failure and has shorter waiting times for heart transplantation than most large metropolitan areas.
And now that its cardiac program has made it an Abiomed Inc. (Danvers, MA) “Center of Excellence,” RWJUH’s heart center is getting stronger every day.
A “Truly Rewarding” VAD
The “Center of Excellence” designation means the hospital is helping set standards for physician training on Abiomed’s ventricular assist devices (VADs), which provide temporary circulatory support for patients in acute heart failure. They also share best practices related to VAD implantation and patient care.
RWJUH’s chief of cardiac surgery Mark Anderson, M.D., led a national study on the use of Abiomed’s VADs titled “Mechanical Circulatory Support Improves Recovery Outcomes in Profound Cardiogenic Shock Post Acute Myocardial Infarction.”
The study found patients who suffered a heart attack followed by cardiogenic shock could recover the natural function of their heart when given Abiomed’s AB5000 circulatory support for an average of 31 days.
Of the patients who were able to survive the traumatic coronary event, 67 percent were able to recover. Dr. Anderson calls the results “truly rewarding.”
“I have found that by utilizing the AB5000, we are able to recover our patients’ hearts and send them home without a transplant, which can be costly and expose these patients to a variety of other problems,” he said.
By providing circulatory support, Dr. Anderson says an injured heart has time to rest. “If given enough time to rest, the cells of the heart can repair themselves,” he said.
And now the center is one of the few hospitals in the country with a fully implantable artificial heart coming its way — RWJUH was chosen in September to offer Abiomed’s newly FDA-approved AbioCor.
Dr. Anderson says 20,000 to 30,000 patients a year could benefit from the technology, according to an article from USA Today.
“There are a million acute heart attacks a year in this country,” he said. “About 70,000 are complicated by shock, and from 30 to 50 percent don’t respond to conventional therapy.”
A two-year study led by Dr. Anderson and financed by Abiomed tracked every patient who received treatment from the device to give their hearts a break after massive heart attacks. The 50-patient study was the first evidence that the device saves lives.
“We’ve basically doubled survival,” Dr. Anderson said. “Not only was survival improved, but nearly 70 percent recovered their native cardiac function. It’s one thing to have a patient survive and go home in heart failure. It’s another to go home with good heart function. The pumps minimize injury to the heart.”
Transmyocardial Revascularization
The center is also one of a few hospitals in the world that offer a new laser procedure to treat inoperable coronary artery disease (CAD).
During transmyocardial revascularization (TMR), a surgeon makes an incision on the left breast to expose the heart. Using a laser, the surgeon drills a series of holes from outside of the heart into the heart’s pumping chamber. From 20 to 40mm laser channels are placed during the procedure.
Bleeding from the laser channels on the outside of the heart stops after a few minutes of pressure from the surgeon’s finger.
In some patients TMR is combined with bypass surgery. In those cases, an incision through the breastbone is used.

Related Content

CDC warning, LivaNova Stockert 3T heater-cooler devices, open-heart surgery patients
News | Cardiovascular Surgery| October 14, 2016
The Centers for Disease Control and Prevention (CDC) is warning healthcare providers and patients about the potential...
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders| October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
3-D bioprinting, 3-D printing, printed organs, 3D bioprinting

3-D printed vessel made from living cells implanted in an animal to test feasibility of using such structures clinically. Blood vessels are a stepping stone to the creation of more complex 3-D printed organs made from biomaterials. Image from the South Carolina Project for Organ Biofabrication.


Feature | 3-D Printing| October 13, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) changed its rules concerning custom medical devices Oct.
Heartware HVAD, ventricular assist device, artificial heart, Medtronic
News | October 05, 2016
October 5, 2016 — Medtronic said two previously communicated global voluntary recalls related to the HeartWare Intern
CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
bundled payments for cardiology, CMS cardiac reimbursements
Feature | Business| September 13, 2016 | John W. Meyer, MPH, FACHE
The movement away from traditional Medicare fee-for-service reimbursement and into bundled payment models by the Depa
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart| September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart| September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
Edwards Intuity aortic valve, surgical aortic valve replacement, PinnacleHealth, first U.S. implants
News | Heart Valve Technology| August 26, 2016
This week, PinnacleHealth, Harrisburg, Pa., became the first hospital in the country to implant the Edwards Intuity...

MRI brain scan of a 26-day-old neonate with Zika virus. It shows septation in the ventricle at the arrow. See more Zika radiology images at http://pubs.rsna.org/doi/full/10.1148/radiol.2016161584.


News | Cardiovascular Surgery| August 26, 2016
August 26, 2016 — As a further safety measure against the emerging Zika virus outbreak, the U.S.
Overlay Init